{"filing":{"accession_number":"0001140361-26-025841","cik":"0001974640","ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"ef20076542_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126025841/ef20076542_8k.htm"},"events":[{"id":12578,"run_id":11157,"accession_number":"0001140361-26-025841","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Apogee entered into two material agreements with Paragon on June 17, 2026: an antibody discovery agreement and an exclusive worldwide license agreement for IL-31R antibodies. The license agreement grants Apogee exclusive rights to develop and commercialize IL-31R-directed antibodies with up to $23.25 million in milestone payments and low-single-digit royalties on net sales. While this is a material contract that would affect a reasonable investor's assessment of the company's pipeline and strategic partnerships, it does not fit the specific M\u0026A, financing, or governance categories—it is a research and development partnership and licensing arrangement that is operational in nature.","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9468,"accession_number":"0001140361-26-025841","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Apogee entered into two material agreements with Paragon on June 17, 2026: an antibody discovery agreement and an exclusive worldwide license agreement for IL-31R antibodies. The license agreement grants Apogee exclusive rights to develop and commercialize IL-31R-directed antibodies with up to $23.25 million in milestone payments and low-single-digit royalties on net sales. While this is a material contract that would affect a reasonable investor's assessment of the company's pipeline and strategic partnerships, it does not fit the specific M\u0026A, financing, or governance categories—it is a research and development partnership and licensing arrangement that is operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:23:09.820362+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9468,"accession_number":"0001140361-26-025841","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Apogee entered into two material agreements with Paragon on June 17, 2026: an antibody discovery agreement and an exclusive worldwide license agreement for IL-31R antibodies. The license agreement grants Apogee exclusive rights to develop and commercialize IL-31R-directed antibodies with up to $23.25 million in milestone payments and low-single-digit royalties on net sales. While this is a material contract that would affect a reasonable investor's assessment of the company's pipeline and strategic partnerships, it does not fit the specific M\u0026A, financing, or governance categories—it is a research and development partnership and licensing arrangement that is operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:23:09.820362+00:00","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-06-22"}]}